FDA Adverse Event Injury Summary report: N

PEPGEN P-15 FLOW

MDR report key: 725779 · Received June 8, 2006

Report

Report Number
1721411-2006-00238
Event Type
Injury
Date Received
June 8, 2006
Date of Event
April 14, 2006
Report Date
May 9, 2006
Manufacturer
DENTSPLY FRIADENT CERAMED
Product Code
NPZ
PMA / PMN Number
P990033
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
DENTIST

Narratives

Additional Manufacturer Narrative · 1

FAILURE TO OSSEOINTEGRATE AND DEVELOPMENT OF INFECTION ARE INHERENT RISKS OF THE PROCEDURE KNOWN TO DOCTOR AND PATIENT BEFORE THE PROCEDURE IS INITIATED AND ARE DEPENDENT ON MANY FACTORS INCLUDING THE PATIENT'S AGE, SEX, HEALTH, AND OCCIAL HISTORY, THE TYPE AND SIZE OF THE DEFECT BEING GRAFTED, AND GRAFT PLACEMENT TECHNIQUE. THESE RISKS ARE INCREASED IN A PATIENT THAT IS A SMOKER IN ADDITION TO THE POTENTIAL SURGICAL COMPLICATION OF ORAL-NASAL COMMUNICATION AND POOR QUALITY BONE. THOUGH PEPGEN WILL REMODEL TO BONE AT A SIMILAR RATE AS NATURAL BONE IN A PATIENT, IT IS IMPOSSIBLE TO DETERMINE THE SPECIFIC RESORPTION RATE OF ANY BONE GRAFTING MATORIAL; MATERIAL PLACED IN AN AREA OF LOW VASCULARITY AND LITTLE OSTEOGENIC POTENTIAL WILL TAKE MUCH LONGER TO REMODEL TO BONE THAN IF PLACED IN A MORE ACTIVE SITE. CONSIDERING THIS AND THE AVAILABLE INFORMATION, THIS EVENT DOES NOT APPEAR TO BE A RESULT OF A MALFUNCTION OF THE DEVICE. THE IMPLANT LOSS WILL BE REPORTED VIA ASR. THE LOT NUMBER WAS PROVIDED FOR EVALUATION, THOUGH RESULTS ARE NOT AVAILABLE AS OF THIS REPORT. EVALUATION RESULTS WILL BE SUBMITTED AS THEY BECOME AVAILABLE. PLEASE REFERENCE REPORT NUMBER 1721411-2006-00237 FOR DOCUMENTATION OF THE EVENT AS IT PERTAINS TO THE PEPGEN P-15 PUTTY USED.510K # P990033

Description of Event or Problem · 1

INFECTION DEVELOPED AND NO OSSEOINTEGRATION WAS ACHIEVED AFTER CONCURRENT PLACEMENT OF PEPGEN P-15 FLOW, PEPGEN P-15 PUTTY, AND AN IMPLANT. AT THE TIME OF IMPLANT PLACEMENT, IT IS NOTED BY THE DOCTOR THAT THERE WAS A POSSIBLE COMMUNICATION BETWEEN THE ORAL CAVITY AND FLOOR OF THE NOSE. ADDITIONALLY, THE DOCTOR STATES THAT AT UNCOVERING, THE IMPLANT FAILED SECONDARY TO MOBILITY AND INFECTION IN THE FORM OF PERI-IMPLANTITIS AND OSTEOLYSIS. AS A RESULT, IT CAN BE PRESUMED THAT ANOTHER SURGICAL PROCEDURE WOULD BE NECESSARY TO ACHIEVE THE DESIRED RESULTS AND PRECLUDE PERMANENT DAMAGE TO A BODY STRUCTURE THAT WOULD NOT BE TRIVIAL.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 PEPGEN P-15 FLOW NPZ NPZ DENTSPLY FRIADENT CERAMED NA P0104096

Patients

Seq Age Sex Outcome Treatment
1 67 YR Required Intervention XIVE 4.5X11 IMPLANT